PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

Inclusion Criteria:

1. Adult males or females aged between 18 and 75 years inclusive

2. Able to give consent for participation on their own or through their LegallyAcceptable Representative (LAR)

3. Able to cooperate in the completion of a standardized neurological examination byISNCSCI standards (excludes patients who are on ventilator)

4. ISNCSCI Impairment Scale Grade "B," "C" or "D" based upon first ISNCSCI evaluationafter arrival to the hospital is classified as motor or sensory incomplete

5. Willing and able to comply with the study Protocol

6. Women must be of non-childbearing potential or surgically sterile or willing to useadequate birth control; men who are sexually active will also be required to useadequate birth control

7. Able to receive the Investigational Drug within 48 hours of injury

8. Neurological Level of Injury between C5-C8, T1-T12, L1-L5 and S1-S5 based upon firstISNCSCI evaluation after arrival to the hospital

9. Patient with incomplete/partial damage/transaction as shown by CT or MRI scan

10. Patients with any other chronic conditions, who are stable with appropriatetreatment

Exclusion Criteria:

1. Previous history related to spinal cord disease

2. Patient on ventilator or requires ventilator

3. Patient with pathological fracture of vertebral column

4. Impairment Scale Grade "A" based upon first ISNCSCI assessment and classified ascomplete injury

5. One or more upper extremity muscle groups un-testable during baseline ISNCSCIexamination

6. Concomitant head injury with a clinically significant abnormality on a head CT (headCT required only for patients suspected to have a brain injury at the discretion ofthe investigator)

7. Females who are breastfeeding or have a positive urine pregnancy test

8. Body mass index (BMI) of ≥35 kg/m2 at screening

9. Known immunodeficiency, including human immunodeficiency virus, or use ofimmunosuppressive or cancer chemotherapeutic drugs

10. Patient having rheumatoid arthritis

11. The participant has a clinically significant cardiovascular disorder or an abnormalelectrocardiogram (ECG) at the discretion of the investigator

12. Pre-existent neurologic disorder which would preclude accurate evaluation andfollow-up (i.e. Alzheimer's disease, Parkinson's disease, any psychiatric disorderwith hallucinations/delusions/schizophrenia)

13. Patients who are currently participating in a clinical trial with an investigationaldrug or investigational device

14. Patients who, in the opinion of the investigator, are otherwise unsuitable for thisstudy